Ascendis Pharma Q2 2026 Product Revenue +105% to €315M; Net Profit €207M
Ascendis Pharma reported strong second quarter 2026 financial results, with total product revenue increasing 105% year-over-year to €315 million. The company achieved an operating profit of €220 million and a net profit of €207 million, or €2.83 per diluted share. Key drivers included robust sales of YORVIPATH®, SKYTROFA®, and YUVIWEL®, along with the sale of a Rare Pediatric Disease Priority Review Voucher for €158 million. Ascendis also settled all outstanding convertible notes and made significant progress in its pipeline, including completing enrollment for the pivotal infant reACHin Trial.
Key Highlights
- Q2 2026 total product revenue increased 105% year-over-year to €315 million.
- YORVIPATH® revenue was €252 million, SKYTROFA® revenue was €55 million, and YUVIWEL® revenue was €8 million.
- Q2 2026 operating profit was €220 million, compared to an operating loss of €53 million in Q2 2025.
- Q2 2026 net profit was €207 million, or €2.83 per diluted share.
- Cash and cash equivalents totaled €812 million as of June 30, 2026.
- Company sold its Rare Pediatric Disease Priority Review Voucher for €158 million cash.
- Settled all $575 million of 2.25% Convertible Senior Notes due 2028, converting them to equity.
- Completed target enrollment for pivotal infant reACHin Trial for YUVIWEL®.
Price Impact
More from ASND
Ascendis Pharma to Present Long-Term Data on Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
Ascendis Pharma Q2 Net Profit €207M, Revenue €339M; YUVIWEL Approved
Ascendis Pharma Q2 Product Revenue €315M, +105% Y/Y